- Poster presentation
- Open Access
[18F]FDDNP performed better than [18F] Florbetapir to distinguish transthyretin cardiac amyloidosis (TTR-CA) patients from healthy controls: an ex vivo study
© Dupont et al. 2015
- Published: 2 November 2015
- Myocardial Tissue
- Cardiac Transplantation
- Adjacent Section
- Cardiac Amyloidosis
TTR-CA is characterized by extracellular depositions of amyloid β (Aβ) which can lead to arrhythmias, heart failure and even sudden death. While early diagnosis of TTR-CA has important therapeutic and prognostic impact, there is no sensitive and quantitative tool to document the location and extent of cardiac Aβ in these patients. So we aimed to test and compare the usefulness for TTR-CA early diagnosis of both [18F]florbetapir and [18F]FDDNP, 2 PET tracers validated for brain detection of Aβ.
Binding of both radiopharmaceuticals to Aβ was evaluated in myocardial tissue from patients who underwent cardiac transplantation either for TTR-CA, or ischemic heart failure as control. Heart sections were incubated with [18F]florbetapir or [18F]FDDNP at concentration of 3nM. Nonspecific binding was assessed by incubation of adjacent sections in the presence of an excess of cold ligand. Autoradiograms were treated with a grey-level analysis method. Regions of interest were delimited and the modal grey value were determined.
[18F]FDDNP uptake in TTR-CA myocardial sections (nP=6) was significantly higher (+86%) compared to controls (nT=3) whereas no significant difference was observed with [18F]florbetapir (nP=4 and nT=2, +32%, p=0.13). The mean ratio (specific binding patient/specific binding controls) were 11.9±2.0 for [18F]FDDNP and 1.5±0.1 for [18F]florbetapir (comparison : p=0.01). Nevertheless, the intensity of both radiotracers binding strongly decreased in sections with unlabeled ligand (-74%, and -83 respectively), suggesting Aβ specificity.
[18F]FDDNP and [18F]florbetapir, are able to bind ex vivo specifically to Aβ in heart tissue. The largely improved ratio of specific binding (patient/controls) of [18F]FDDNP, compared to [18F]florbetapir, strongly suggests its better sensibility and then diagnostic potential to discriminate in vivo ATTR patients from healthy subjects.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.